Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment

Breast Cancer Research and Treatment

Volumn 85, Issue 1, 2004, Pages 53-63

  Christensen, G L ^a   Jepsen, J S ^a   Fog, C K ^a   Christensen, I J ^b   Lykkesfeldt, A E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Antiestrogens; Bcl 2; EB1089; Growth inhibition; Predictive markers; Resistance; Sequential versus combined treatment; Vitamin D receptor

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PROTEIN BCL 2; SEOCALCITOL; TAMOXIFEN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCITRIOL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; GENES, BCL-2; HUMANS; PREDICTIVE VALUE OF TESTS; RECEPTORS, CALCITRIOL; RECEPTORS, ESTROGEN; TAMOXIFEN; VITAMIN D;

EID: 1842502620     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000021047.37869.95     Document Type: Article

References (29)

1. American Cancer Society: Cancer facts and figures, www.cancer.org, 2002
2. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606, 2001
3. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767, 2000
4. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1: 16-19, 1985
5. Dowsett M, Ellis MJ: Role of biologic markers in patient selection and application to disease prevention. Am J Clin Oncol 26: S34-S39, 2003
6. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338, 1995
7. Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE: Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585-589, 1997
8. Osborne CK, Yochmowitz MG, Knight III WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980
9. Blichert-Toft M, Ejlertsen B, Mouridsen H, Overgaard M: Breast cancer. Ugeskr Laeger 164: 3023-3026, 2002
10. Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL: A phase II trial of the vitamin D analogue Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. Br J Cancer 86: 680-685, 2002
11. Hansen CM, Hamberg KJ, Binderup E, Binderup L: Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 6: 803-828, 2000
12. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC: EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44: 2273-2280, 1992
13. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT, Combes RC: Topical calcipotriol treatment in advanced breast cancer. Lancet 337: 701-702, 1991
14. Nolan E, Donepudi M, VanWeelden K, Flanagan L, Welsh J: Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells. Mol Cell Biochem 188: 13-20, 1998
15. Larsen SS, Heiberg I, Lykkesfeldt AE: Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer 84: 686-690, 2001
16. Hansen CM, Rohde L, Madsen MW, Hansen D, Colston KW, Pirianov G, Holm PK, Binderup L: MCF-7/VD(R): a new vitamin D resistant cell line. J Cell Biochem 82: 422-436, 2001
17. Jensen SS, Madsen MW, Lukas J, Bartek J, Binderup L: Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with vitamin D receptor protein induction. J Steroid Biochem Mol Biol 81: 123-133, 2002
18. Mathiasen IS, Lademann U, Jaattela M: Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59: 4848-4856, 1999
19. Briand P, Lykkesfeldt AE: Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res 44: 1114-1119, 1984
20. Lykkesfeldt AE, Briand P: Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 53: 29-35, 1986
21. Lykkesfeldt AE, Larsen SS, Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61: 529-534, 1995
22. Lundholt BK, Briand P, Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 67: 199-214, 2001
23. Slinker BK: The statistics of synergism. J Mol Cell Cardiol 30: 723-731, 1998
24. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408-414, 1994
25. Fisher B, Fisher ER, Redmond C, Brown A: Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res Treat 7: 147-160, 1986
26. McGuire WL: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433, 1978
27. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C, Safe S: Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274: 32099-32107, 1999
28. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J: Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42: 31-41, 1997
29. Vink-van Wijngaarden T, Pols HA, Buurman CJ, van den Bemd GJ, Dorssers LC, Birkenhager JC, van Leeuwen JP: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54: 5711-5717, 1994